The value of cardiopulmonary exercise testing in sarcoidosis
Normal pulmonary function tests (PTFs) do not always predict functional limitations during exercise in sarcoidosis. Cardiopulmonary exercise testing (CPET) may facilitate in recognition of exercise intolerance in these patients. A relevant data in sarcoid patients are limited, including spirometry, DLCO and lung volumes and CPET using standard protocol, 83 sarcoid patients consecutively referred for evaluation of exertional dyspnea over a 3-year period. Patients were grouped according to their radiologiacal stages as Stage I: 43, Stages II-III: 31 and Stage IV: 9. VO2 peak was decreased (
CONCLUSIONS: Children with sarcoidosis seem to respond well to systemic steroids and low dose methotrexate. Delayed diagnosis and ocular involvement are probably associated with poor outcome. PMID: 30806359 [PubMed - in process]
Conditions: Sarcoidosis, Pulmonary; Sarcoidosis Lung; Sarcoidosis Interventions: Drug: Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial; Diagnostic Test: Spirometry; Genetic: RNA Sequencing; Diagnostic Test: Laboratory testing; Drug: Corticosteroid; Drug: Tofacitinib 5mg [Xeljanz] 1 year open-label extension Sponsors: Oregon Health and Science University; Pfizer Not yet recruiting
Conclusion: IOS is a good modality to detect small airway dysfunction in early stages and certain occupational ILD where spirometry may remain normal and can be used as an adjunct to spirometry both for diagnosis and follow up of therapeutic outcomes in ILD.
Background: Lung function and exercise performance in sarcoidosis are affected by both, lung and cardiac involvement. Data regarding the impact of heart involvement on lung function in cardiac sarcoidosis (CS) is limited.The aim of this study was to assess and compare results of spirometry, lung volumes, transfer factor for carbon monoxide (TL,CO) and six-minute walking test (6MWT) in patients with and without heart involvement.Methods: A retrospective analysis of pulmonary function tests and 6MWT in the group of biopsy-proven sarcoidosis patients with heart involvement detected or excluded in the cardiovascular magnetic r...
This study aimed to evaluate the aforementioned tests, in order to examine the functional capacity of sarcoidosis patients, in different stages.Methods: This cross-sectional study carried out, on 50 Iranian patients with sarcoidosis. Patients were classified into three groups, based on the findings of the chest radiography, as well as the pulmonary CT scan, performed by an expert Radiologist; Pulmonary, cardiac and activity function have been evaluated in the patients, using CPET, 6MWT and spirometry.Results: In CPET, percent-predicted peak VO2, 57.75±15.49, p
Conclusion: Sex differences seems to not have any influence on lung function while smoking affects TL, CO results but not spirometry, particularly signs of airway obstruction, in sarcoidosis patients.
To address the reliability of CT activity score (CTAS) and investigate the relationships between CTAS, lung function changes after treatment and the serum angiotensin-converting enzyme (SACE) levels. Fifty-seven sarcoidosis patients underwent chest high-resolution CT (HRCT) and spirometry, as well as SACE examination, were retrospectively analyzed. Follow-up spirometry in each patient was obtained about 6 months after the initial spirometry. The correlations between CTAS and pulmonary function changes were evaluated by Spearman correlation analysis. According to SACE status, patients were divided into normal and high leve...
CONCLUSIONS: FDG-PET scan can be used as an important adjunct non-invasive investigation in diagnosing and monitoring of various benign lung conditions. It also helps in assessing whole body disease burden which may change therapeutic decisions. PMID: 30152649 [PubMed - in process]